NCT06707649 The Effectiveness of Self-Management Education and Telephone Follow-up in Patient with COPD Exacerbation
| NCT ID | NCT06707649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kirsehir Ahi Evran Universitesi |
| Condition | COPD (Chronic Obstructive Pulmonary Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-09-01 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
According to the 2024 GOLD guidelines, Chronic Obstructive Pulmonary Disease (COPD) is defined as heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. COPD is one of the leading causes of mortality and morbidity in Turkey and worldwide. Since COPD is an incurable and lifelong disease, it is important for patients to have high levels of self-management. The main questions it aims to answer are: 1. Does self-management education and telephone follow-up intervention effect self-care agency and symptom management in people with COPD exacerbation? 2. Does self-management education effect self-care agency and symptom management in people with COPD exacerbation? This study will evaluate the effect of self-management education and telephone follow-up on self-care agency and symptom management. Patients hospitalized with COPD exacerbation will be trained in the hospital and will be followed up by phone call after discharge. During the study, 3 groups were planned; Group 1 will be educated and followed up by telephone Group 2 will only receive education and no telephone follow-up. Group 3 will not receive education and telephone follow-up, only standard care. It is planned to collect the data from the patients at the beginning of the study, at 1, 3 and 6 months. Main outcomes: * Level of self-care agency * Level of symptom management The results obtained will be interpreted by comparing between 3 groups.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with COPD for the last 1 year * Diagnosis of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III or IV COPD documented by pulmonary function testing * Patients hospitalized for acute exacerbation of COPD; * Hospitalized for at least 3 days * Having a personal mobile phone and the ability to use it, * Being enough conscious and oriented to answer the questions, * Voluntary patients Exclusion Criteria: * Under 18 years old * Withdrawal from the study at any phase * Inability to be contacted by phone/mobile phone, * Patient death
Contact & Investigator
Yasemin CEYHAN, PhD
PRINCIPAL INVESTIGATOR
Kirsehir Ahi Evran Universitesi
Frequently Asked Questions
Who can join the NCT06707649 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06707649 currently recruiting?
Yes, NCT06707649 is actively recruiting participants. Contact the research team at yasemin-ceyhan@hotmail.com for enrollment information.
Where is the NCT06707649 trial being conducted?
This trial is being conducted at Kırşehir, Turkey (Türkiye).
Who is sponsoring the NCT06707649 clinical trial?
NCT06707649 is sponsored by Kirsehir Ahi Evran Universitesi. The principal investigator is Yasemin CEYHAN, PhD at Kirsehir Ahi Evran Universitesi. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.